For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Europe opioid-induced constipation drug market is expected to grow at a CAGR of 7.51% during the forecast period of 2017-2025. The market value is predicted to increase from $1497million in 2016 and reach up to $2877 million by the end of 2025.
The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs such as naloxegol, methyl naltrexone bromide, lubiprostone, others. Of these, lubiprostone is currently the most popular drug type in the region. The second market segmentation criteria is on the basis of the type of prescription that includes over the counter drugs and branded or generic prescribed drugs. The over the counter drugs are more popular as compared to the prescribed ones due to their ease of availability.
Some of the noted companies in the market include Pfizer, Daiichi Sankyo Co Ltd, Theravance Biopharma Inc, Progenics Pharmaceuticals Inc, Allergan Plc, Purdue Pharma L.P., Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa,C.B. Fleet Company, and Nektar Therapeutics.